.jpg?format=webp&width=780)
A study highlighted the potential of Buprenorphine Extended-Release (XR) in treating Opioid Use Disorder (OUD) during the postpartum period. The study involved 15 postpartum patients who received buprenorphine-XR injections. Results showed that 80% tested negative for opioids, excluding buprenorphine, reported no euphoria or intoxication, and 20% discontinued treatment. This extended-release monthly injection could hold promise for treating OUD in this high-risk group.
Like
Save
Share